The Week

Beam Therapeutics (BEAM) fell 19.12% this week to $23.99, while the S&P 500 slipped 0.8%, leaving the stock about 18.32 percentage points behind the benchmark. The move was one-directional: Tuesday opened at $26.76, touched $27.30, then faded to $26.83; Wednesday slid to $25.175; Thursday broke below $25 to close at $24.37; Friday traded in a tight range, dipping to $23.95 before settling at $23.99, right at the low of the week. Over a 60-day window, $23.95 marks the bottom of the range.

Key Events

The week centred on the updated Phase ¹⁄₂ data for BEAM-302 in AATD presented at the European Respiratory Society Congress on 8 September. Multiple reports said BEAM-302 showed durable efficacy and safety and pointed to an accelerated approval path. The market reaction was soft, however—shares dropped the next day and landed in the day’s top losers list. Wedbush subsequently reaffirmed its buy rating, citing a strengthened clinical profile and a clearer accelerated approval path despite the broader pullback. Late in the week, a law firm said it was investigating claims on behalf of investors, adding to the negative sentiment.

Analyst Ratings

As of this week, 15 institutions cover Beam: 12 rate it buy, 1 overweight, 2 hold, and none underweight or sell. The consensus rating is strong buy, with a consensus target of $52.15385, about 117.40% above the $23.99 spot. Targets range from $26.00 to $80.00, showing wide dispersion. Beam ranks 56th out of 506 in its biotechnology sector, in the upper-middle band.

The Week Ahead

The next week brings a dense slate of US macro data. The New York Fed manufacturing index lands on Tuesday 15 September, followed on Wednesday 16 September by retail sales, retail sales ex-autos, import prices, the NAHB housing market index and weekly EIA crude inventories. The market will watch whether retail numbers can bounce from a weak prior reading. For Beam, the digestion of the BEAM-302 update and any follow-through from the investor claims investigation remain key items to track.

In Short

Broker ratings sit at strong buy with a target far above spot, yet the BEAM-302 update did not hold the stock up—down nearly 19% for the week, back at the bottom of its 60-day range. On the latest trading day, large orders were net sellers while medium and small orders were net buyers, with no big-money follow-through. The next test is whether next week’s macro data and the BEAM-302 story can stabilise sentiment or extend the pullback.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.